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Abstract: Growth hormone (GH) was first used to treat a patient in 1958. For the next 25 years it 
was available only from cadaver sources, which was of concern because of safety considerations 
and short supply. In 1985, GH produced by recombinant DNA techniques became available, 
expanding its possible uses. Since that time there have been three indications approved by the US 
Food and Drug Administration (FDA) for GH-deficiency states and nine indications approved 
for non-GH-deficiency states. In 2003 the FDA approved GH for use in idiopathic short stature 
(ISS), which may indirectly cover other diagnoses that have short stature as a feature. However, 
coverage for GH therapy is usually more reliably obtainable for a specific indication, rather than 
the ISS indication. Possible future uses for GH therapy could include the treatment of syndromes 
such as Russell–Silver syndrome or chondrodystrophy. Other non-short-stature indications could 
include wound healing and burns. Other uses that have been poorly studied include aging and 
physical performance, in spite of the interest already shown by elite athletes in using GH. The 
safety profile of GH developed over the past 25 years has shown it to be a very safe hormone 
with few adverse events associated with it. The challenge for the future is to follow these patients 
into adulthood to determine whether GH therapy poses any long-term risks.
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Background
The first report of the use of growth hormone (GH) therapy for GH deficiency (GHD) 
was in 1958.1 Early GH preparations used therapeutically were derived from human 
cadaver pituitaries. In the USA, human-derived GH was produced and distributed by 
the National Institute of Health’s (NIH) National Pituitary Agency. The preparation 
was in short supply, resulting in lower than ideal dosing and frequent drug holidays. 
Potential recipients were required to participate in a research protocol and, to ration 
the cadaveric GH, the diagnosis of GHD required that the patient have a peak GH level 
in response to provocative stimuli below a certain level. This requirement gradually 
increased in response to a better supply of cadaveric GH, starting at 5 ng/mL, then 
7 ng/mL, and finally 10 ng/mL in the early 1980s. In 1985 this preparation was linked 
to a risk for Creuzfeldt–Jacob disease,2,3 and its use was discontinued. In 1979 GH was 
produced in large quantities by expressing the human GH gene in Escherichia coli.4 
In 1985, Genentech Inc (San Francisco, CA) was approved by the US Food and Drug 
Administration (FDA) to market recombinant human GH (rhGH),5 a product   identical 
to human GH with the addition of a methionine, which was necessary as a start signal 
for the bacteria to initiate protein synthesis. Use of methionyl GH did result in anti-
body production, but this was rarely associated with growth attenuation.6 Present-day Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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commercial preparations all have the identical 191 amino acid 
sequence of native human pituitary hormone.7
Initially GH was injected intramuscularly, but in the 
  mid-1980s (about the time rhGH was introduced), it was 
shown to be as effective if given as a subcutaneous injection,8 
which remains the practice today. Early in its use, GH was 
given twice weekly but this was was increased to three times 
weekly when the higher frequency was shown to result in an 
increased growth response.9 At about the time of the transition 
from cadaveric GH to rhGH, it was demonstrated that daily 
doses (six or seven injections per week) yielded an even better 
growth response than the three times per week schedule,10–13 
and daily administration is commonly used today. It is now 
clear from data from large databases14–16 that GH-deficient 
children treated with GH are frequently achieving adult 
heights in the normal adult range, probably as a result of more 
aggressive dosing, dividing the dose into daily injections, 
and, perhaps, earlier initiation of treatment.
Since 1985 there have been eight indications for GH 
therapy in children approved by the FDA, and an additional 
indication for increasing the dose during puberty (see 
Table 1). There have also been three indications for GH use 
in adults. The basis for these indications has recently been 
reviewed.17
Fifteen years ago, Hintz18 reviewed current and potential 
uses of GH. At that time, GH was already FDA approved in 
childhood GHD and chronic renal insufficiency, and adult 
GHD, Turner syndrome, and acquired immune deficiency 
syndrome (AIDS) wasting were on the brink of FDA 
approval.
Hintz predicted that other indications that might even-
tually have FDA approval for treatment of short stature 
included what he referred to as “non-growth hormone 
deficient short stature,” which we now call “idiopathic 
short stature” (ISS), skeletal dysplasia, spina bifida, rickets, 
Prader–Willi   syndrome, and Down syndrome. Of these 
indications, Prader–Willi syndrome was FDA approved in 
2000 and ISS was approved in 2003. The ISS indication has 
also been approved in Canada and parts of Latin America, 
although there has not yet been approval in Europe. FDA 
approval in the USA is limited to non-GHD patients whose 
height is >2.25 standard deviations (SDs) below the mean, 
who have predicted adult heights that are >2 SDs below the 
mean, who have open epiphyses, and who have no other 
condition that would better be treated by other means or by 
observation. There has also been interest in the use of GH as 
an anabolic agent in situations in which stature is not of para-
mount importance. Certainly, the anabolic effects of GH are 
of primary importance in the treatment of adults with GHD, 
where it has been shown to reduce accumulation of intra-
abdominal fat, reverse high levels of low-density lipoprotein 
cholesterol, increase bone mineral density, and reverse some 
of the symptoms of fatigue. In the treatment of Prader–Willi 
syndrome, one of the benefits is increase in muscle mass at 
the expense of fat mass, which serves to improve overall body 
composition along with improvement in hypotonia, which 
is a major feature of the syndrome. However, it should be 
pointed out that FDA approval of treatment of Prader–Willi 
syndrome was limited to being for the short stature that is a 
part of the syndrome.
Other possible uses for GH that Hintz18 mentions 
include non-islet cell tumor hypoglycemia, fertility, aging, 
wound healing, cancer cachexia, and amyotrophic lateral 
sclerosis.
Potential indications for increased 
height
FDA approval of the ISS indication in 2003 has allowed 
GH to be used for a number of diagnoses that are not GHD. 
However, it has been difficult to get payers to cover the cost 
of treating ISS with GH. It is recognized that ISS represents a 
heterogeneous group of patients who are experiencing growth 
failure for a variety of reasons, and as more is understood 
about the etiology of growth failure, many of these patients 
will have more specific diagnoses. Screening of ISS patients 
for abnormalities in the SHOX gene has been a logical step. 
Out of 91 patients with ISS screened, Rao et al reported one 
patient with a functionally significantly mutation in the SHOX 
gene.19 Ogata expanded the screen to include 400 patients 
with ISS, and found the aforementioned patient, along with 
Table 1 Approved indications for GH use in the USA and europe
Indication Year of FDA approval
GH-deficiency states
Childhood growth-hormone deficiency 1985 (e)
Adult growth-hormone deficiency 1996 (e)
Pubertal dosing 2000
Non-GH-deficiency states
Chronic kidney disease 1993 (e)
Turner syndrome 1996 (e)
AiDS wasting 1996
Prader–willi syndrome 2000 (e)
Small for gestational age 2001 (e)
idiopathic short stature 2003
Small bowel syndrome 2004
SHOX deletion 2006 (e)
Noonan syndrome 2007
Abbreviations: e, europe; FDA, US Food and Drug Administration; GH, growth 
hormone.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
413
Options in growth hormone therapy
three others had SHOX gene mutations.20 In an analysis of 
68 patients with ISS, one female patient was identified who 
had a normal karyotype but a deletion of one SHOX allele.21
Other genes that have recently been discovered to result 
in growth failure include defects in the GH receptor’s 
intracellular signaling, in particular STAT5b,22 and a 
defect in the acid-labile subunit (ALS) of the circulating 
insulin-like growth factor 1 (IGF-I) complex.23 STAT5b   
deficiency results in a phenotype of GH insensitivity and 
immunodeficiency, while ALS-deficient patients have rather 
subtle growth failure with height tracking at about or just 
below the third percentile. Neither of these defects has been 
identified in patients diagnosed as having ISS,24,25 perhaps in 
part because they represent very rare disorders. Also, it has 
been pointed out that the phenotype of STAT5b deficiency is 
that of severe GH resistance, and it is not likely to be mistaken 
for ISS.25 Perhaps ALS deficiency has not been identified 
in a population of ISS patients because the growth failure 
associated with it is too subtle for the affected child to be 
labeled as having ISS.
It appears that mutations in the GH receptor and the SHOX 
gene account for 1%–5% of the cases of growth failure that 
are designated ISS. As we recognize various causes for ISS, 
the pool of children with this designation should continue 
to decrease.26
An analysis of patients in a large database27 showed that, 
between 1985 (when rhGH was first used) and 2003, over 
8000 patients had been treated for ISS at a time when the 
database included data from 47,226 total patients. When 
subgroups of these patients were evaluated for their growth 
patterns, it was clear that they started GH therapy with very 
short stature (−3.2 to −2.8 SD). Except for those who had been 
in puberty at the start of therapy, patients were followed for 
7 years, at which time mean heights were −1 to −1.2 SD.
What have been the repercussions relating to the 
FDA approval of ISS as an indication for GH treatment? 
A   comparison was made of data in the National Cooperative 
Growth Study from children who were treated for ISS before 
2003 and those treated from 2003 to 2006 (ie, after FDA 
approval).28 Although no major changes were seen, there was 
a very small decrease in the severity of the growth retardation 
at entry and a slight increase in the treatment doses. Mean 
height velocities during treatment were the same before and 
after FDA approval.
An evaluation of iSS patients
Since FDA approval of GH treatment for ISS in 2003, there 
have been several new indications that are for conditions or 
syndromes in which short stature is part of the condition. 
To date, these have included the SHOX deletion (including 
  Léri–Weill syndrome)29 and Noonan syndrome. Another 
possible situation in which GH might be used would be for 
children with skeletal dysplasias. However, a recent study 
suggests that children with skeletal dysplasias respond poorly 
to GH therapy.30 A previous study evaluated 5 years of GH 
therapy in 35 children with achondroplasia.31 Patients were 
randomized to one of two dosing arms: 0.1 IU/kg or 0.2 IU/kg. 
The group receiving the higher dose increased their average 
height by 0.8 SD during the study; the group receiving the 
lower dose increased their average height by 0.6 SD. They 
saw no change in body proportions or arm span.
There has also been some interest in treating children 
with Russell–Silver syndrome with GH. A recent study 
treated 26 patients with Russell–Silver syndrome to adult 
height (median treatment time: 9.8 years).32 Over this time, 
the mean height SD of the patients increased from −2.7 to 
−1.3. It was also noted that those patients with the shortest 
height SD at the beginning of GH therapy were the ones that 
gained the most height with treatment.
Hypophosphatemic rickets
Hypophosphatemic rickets also includes, autosomal 
dominant hypophosphatemic rickets, autosomal recessive 
hypophosphatemic rickets, tumor-induced osteomalacia, 
and fibrous dysplasia. All of these disorders are charac-
terized by low levels of serum phosphate, which does 
not allow good function of mature osteoblasts, leading to 
poor linear growth. X-linked hypophosphatemic rickets 
(XLHR) is the most common form of hypophosphatemic 
rickets. Conventional therapy has included supplementation 
with oral phosphate and vitamin D. Growth response to 
conventional therapy is disappointing, in part because oral 
phosphate is unpalatable and there is often noncompliance. 
Since the advent of recombinant GH, there has been   interest 
in investigating whether GH would increase the growth 
response (and ultimately adult height) in patients with this 
disorder. Due to the rare nature of the disorder, such studies 
have been limited because of the small numbers of subjects 
studied. Saggese et al studied twelve subjects, of whom six 
received conventional therapy plus GH and six received 
only conventional therapy.33,34 They concluded that those 
receiving GH showed an increase in height Z-score, growth 
velocity Z-score, and predicted adult height, along with 
increases in serum phosphate, bone markers, bone alkaline 
phosphatase, parathyroid hormone, 1,25-hydroxy vitamin D,   
and bone mineral density. Reusz et al similarly treated   Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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six children with XLHR with GH, and showed an increase 
in height Z-score and a slight increase in serum phosphate.35 
However, there was no control group in this study.   Wilson 
reviewed seven clinical trials and concluded that GH appeared 
to increase growth velocity, although there were no adult 
height data.36 He did note that GH therapy appeared to be 
safe. A subsequent study did report adult height data in a 
study of treating twelve patients with XLHR (six treated 
with conventional therapy plus GH, and six treated only 
with conventional therapy).37 These results showed that 
GH treatment for as long as 10 years was associated with 
an increase in height SD score of 1 SD at the time adult 
height was achieved. Another analysis of published data by 
Huiming and Chaomin found that, of the five published trials 
they found, only one met their inclusion criteria.38 This trial 
included only five participants, but it did show an increase 
in height SD score with GH. However, their conclusion was 
that there was no conclusive evidence that GH therapy in 
XLHR increased linear growth, changed mineral metabolism, 
renal function, bone mineral density, or body proportions. 
However, GH therapy did appear to be safe.
It seems clear, therefore, that treatment with GH is safe 
for hypophosphatemic rickets, but it is not yet possible to 
say whether GH treatment is truly effective, or, if there is 
a growth response, how large an increase in adult height 
there would be. More investigation with appropriate con-
trols and greater numbers of subjects is necessary before it 
can be conclusively determined that GH is of benefit in this 
condition.
Psychological aspects of treating short 
stature with GH
It is assumed that short stature is associated with 
disadvantages and problems of psychological adjustment. 
Anecdotal reports include teasing, treating children in rela-
tion to their height rather than their age (juvenilization), 
and academic underachievement.39 Some studies seem 
to confirm these notions,40–43 while others have failed to 
demonstrate any   disadvantage to short stature, including 
any problem with psychological adjustment.44–47 In fact, 
Kranzler et al48 evaluated 90 children who were sent to a 
stature clinic and determined that, in fact, they had normal 
psychological function without externalizing behavior 
problems, attention problems, or poor social skills, as had 
been previous reported.42,49,50 Sandberg et al reported that 
juvenilization does occur, but short stature is not associated 
with any social disadvantage.51 Balen et al have suggested 
that patients referred for ISS seem to be more at risk for 
psychological problems than those who are not referred.52 
  Further, they indicate that in addition to stature there are 
other risk factors for psychological difficulty, including: 
being juvenilized, being male, having low intelligence, 
  having a younger but taller sibling, and being part of a 
family with low socioeconomic status. In light of this 
controversy, it is not surprising that it has been difficult 
to demonstrate that treatment of short stature improves 
the quality of life of the individual. Many physicians who 
treat children with ISS believe that by increasing adult 
height they are improving quality of life;53 however, there 
are few objective data to support this notion.54 In fact, the 
idea that short stature is a problem that can be addressed 
by GH treatment has been recently challenged in the 
popular press.55 Recent reviews of available instruments 
for evaluating quality of life in children with GHD or ISS 
suggest that it should be possible to do studies that could 
help answer whether treatment with GH has a positive or 
negative effect on quality of life.56,57 Chaplin et al have 
recently published a study on the effect of GH therapy 
on behavior and   psychosocial characteristics in 99 short 
children treated with GH (32 with GHD and 67 with ISS).58 
They demonstrated that at baseline these children showed 
higher levels of internalizing behavior and self-esteem 
compared with reference values. With GH treatment, 
behavior measures and depression became closer to the 
population mean at 3 months. Further, this change was 
maintained for as long as 24 months. We should expect 
further studies along this line to know whether GH therapy 
for short stature is   effective beyond merely making chil-
dren taller. This question is particularly relevant because 
of the expense of GH therapy – which costs perhaps as 
much as US$52,634/inch.59 Savage has suggested that for 
non-GHD short stature, (1) if GH therapy is restricted to 
a height threshold of –2.5 or –3.0 SD and, (2) if treatment 
is limited to those children with slow height velocity, there 
might be fewer children who would experience a benefit 
in terms of taller stature that could have been attained 
without treatment.60
As previously discussed,61 there are a number of reasons 
to treat children with ISS, the most important of which is that 
it does not seem appropriate to withhold treatment from them 
just because the etiology for their extreme short stature has 
not yet been discovered. With time there will likely be a larger 
group of patients in which the etiology of their short stature is 
elucidated. Other approaches to treating ISS include treating Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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with IGF-I (alone or in combination with GH), which has 
the added risk of adverse events, or delaying puberty, either 
with LHRH agonists or with an aromatase inhibitor. Both of 
these approaches are still in experimental stages.
Potential indications, both  
height-related and anabolic
Cystic fibrosis
Cystic fibrosis (CF) is an autosomal recessive disorder 
caused by mutation of the CF transmembrane regulator pro-
tein, which regulates sodium and chloride transport across 
epithelial membranes. CF is characterized by viscous secre-
tions of exocrine glands, endocrine pancreas insufficiency, 
as well as growth failure and malnutrition. Since the advent 
of recombinant GH there has been interest in using GH to 
treat the growth issues, as well as to help address some of the 
nutritional problems relating to their increased energy expen-
diture. Several studies have suggested that GH therapy in CF 
increases growth velocity as well as weight.62,63 A recent study 
evaluated ten controlled clinical trials and eight observational 
studies. In the controlled trials, markers of pulmonary func-
tion, anthropometrics, and bone mineralization all appeared 
to be increased compared with controls. The single-case 
studies tended to support these findings. With regard to 
long-term health issues, such as pulmonary exacerbations, 
hospitalizations, or mortality, the only significant finding was 
that GH therapy seemed to reduce the rate of hospitalizations. 
Therefore, data for treatment of CF appear promising but 
more studies are necessary to determine whether there are 
long-term benefits of this treatment.
Potential nonheight-related indications
Critically ill patients
In the 1990s, there was interest in treating catabolic patients 
with GH. Two large placebo-controlled studies were under-
taken in intensive care patients who had heart or abdominal 
surgery, trauma, or acute respiratory failure. Both studies 
were concluded early when an interim evaluation of the 
data demonstrated that the mortality rate in both studies was 
significantly higher in those patients receiving GH (41.9% 
versus 19.3%).64,65 It is now recommended not to treat criti-
cally ill patients with GH, especially patients with an active 
infection or sepsis.
Burns
GH was used soon after recombinant GH was available to 
increase donor site healing in patients with severe burns.66 
Lal et al demonstrated that patients receiving large doses of 
GH (0.2 mg/kg/day) had an approximately 14-day decrease 
in length of stay.67 Because of concern about increased 
mortality seen in critically ill adults, they compared mor-
tality rates between these patients and a control group. 
Mortality rates for those receiving GH were not different 
from controls.
Aging
It has been noted that there is a decline of about 14% per 
decade of age in the levels of both GH and IGF-I.68 Because 
some of the signs of human aging, such as decreased muscle 
and bone mass, dyslipidemia, and psychological symptoms, 
are similar to what has been seen with adult GHD, it has been 
suggested that these signs of aging may be due, at least in 
part, to the low levels of GH and IGF-I, and has even been 
given the description “somatopause.” Unfortunately, studies 
using GH replacement in subjects with somatopause have 
been somewhat disappointing.69–71
Physical performance
The problem of the use of GH as a performance enhancer 
has been well recognized in the world of sports.72 It is 
used for its anabolic and lipolytic properties in an attempt 
to improve performance and shorten recovery times after 
injury. In studies with healthy untrained men, addition of 
GH to resistance training for 12 weeks failed to increase 
muscle strength beyond what was gained by training 
alone.73 Further, Yarasheski et al have demonstrated that GH 
administration does not increase muscle protein synthesis 
in experienced weight lifters.74 However, Birzniece et al 
have suggested that GH could affect utilization of metabolic 
fuels during exercise, leading to enhancement of exercise 
  capacity.72 Although GH does increase lean body mass, 
Birzniece et al suggest that it is likely due to fluid retention, 
rather than increased muscle mass.72 These authors 
acknowledge that, while GH does not increase muscle 
strength, power, or aerobic capacity in healthy adults, it does 
appear to increase anaerobic capacity. While the ability of 
GH to increase sprint capacity justifies its ban in sports, it 
may offer an option of improving physical rehabilitation, 
as well as physical function and independence in disabled 
or injured patients.
Safety of GH
GH adverse events have been carefully documented in 
a review of GH therapy.75 Most adverse events have Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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been local-injection-site reactions, which rarely lead to 
  discontinuation. Headache, nausea, and fever have been 
generally self-limiting and are well tolerated. Adverse events 
such as edema or carpal tunnel syndrome are seen more 
often in adults than children, and may be the result of fluid 
retention caused by GH.68 Adverse events seen particularly 
in children have included transient idiopathic intracranial 
hypertension (IIH, also known as pseudotumor cerebri), 
gynecomastia, and slipped capital femoral epiphysis.76,77 
The IIH resolved after discontinuation of GH and restarting 
at a low dose.
There has been particular interest in evaluating the 
safety of GH treatment of children with ISS, since these 
children are often described as “normal short children.” 
Thus, it would be of concern if treating these particular 
children with GH put them at any significant risk. 
  Therefore, this group of children has been extensively 
studied from a safety perspective. An evaluation by 
  Quigley et al78 of safety data from the controlled trial of 
GH therapy of children with ISS79 and the subsequent 
dose response study,80 as well as an evaluation of >8000 
ISS patients followed in a large postmarketing database 
for children treated with GH,27 have shown that there are 
no safety issues in GH therapy different from those seen 
with treatment of GHD.
There have been concerns about cancer associated 
with GH administration. These issues have been recently 
reviewed.68 Acromegaly is known to increase the risk of 
colorectal cancer.81 Epidemiological studies have shown 
a relationship between tall stature and cancer risk,82 
between IGF-I levels and the risk of prostate cancer,83 and 
an increase in breast cancer associated with levels of free 
IGF-I.84 One study has suggested that there may be cause 
for concern because of cases of Hodgkin’s disease and 
colorectal cancer found in long-term follow-up of patients 
who had received human-derived GH.85 Although the 
incidence of these diseases was greater than the population 
at large, it was not outside the confidence ranges. Further, 
follow-up of patients receiving human-derived GH in the 
USA has not shown such a correlation.85 There has been 
recent concern from analysis of data in French children who 
were treated with GH between 1985 and 1996, and then 
followed until 1996 (the Safety and Appropriateness of 
Growth hormone treatments in Europe [SAGhE] study).86 
A retrospective analysis of mortality in this population 
suggests the possibility of increased cardiovascular disease 
and bone tumors in adults who received GH as children. 
The cardiovascular disease was primarily attributed to 
subarachnoid or intracerebral hemorrhages. Overall cancer 
mortality rates were not higher than the general population, 
but bone tumor–related deaths were five times higher 
than expected. There appeared to be a dose relationship 
(risk was highest in patients receiving doses >50 mcg/
day). However, there was no apparent relationship with 
duration of GH therapy, which would be expected if the 
increase in mortality was actually related to GH therapy. 
Data from other European countries should be available 
over the next several years, and may serve to shed some 
light on the SAGhE data. A recent report has examined 
life expectancy in 99 Ecuadorian people with GH receptor 
deficiency (GHRD) – that is, who had a defect in their 
GH receptor leading to IGF-I deficiency.87 The GHRD 
population had only one cancer (nonfatal), compared 
with 17% of the control population. Further, there were 
no cases of diabetes in the GHRD population, compared 
with 5% in the control population. This study provides 
strong evidence that the GHRD population has resistance 
to cancer and diabetes.
Overall, GH has been shown to be a safe hormone when 
used at recommended doses. There are excellent large data-
bases for evaluation of possible safety signals that occur 
during treatment with GH, such as the National Cooperative 
Growth Study (NCGS) and the Kabi International Growth 
Study (KIGS) What is most needed is long-term adult 
follow-up of those patients who received GH as children.
Conclusion
From careful studies over the past 25 years, GH appears to 
be a relatively safe hormone, at least during the time that it is 
being administered. There are few data relating to long-term 
follow-up, and this is a challenge for the future. GH is a pow-
erful growth-promoting anabolic   hormone, which may have 
further use in treating a number of short stature conditions, 
for example Russell–Silver syndrome or   chondrodystrophies, 
as well as X-linked vitamin D–resistant rickets. When used to 
treat CF it may offer stimulation of linear growth, as well as 
better energy balance. GH should not be used in critically ill 
patients, since it has been associated with increased mortality 
in this population. It may possibly offer benefit in situations 
of muscle wasting, including aging, and it does appear to 
offer some advantage in physical performance, which may 
lead to uses in treating injured patients who could   benefit 
from increased physical function and independence. Further 
studies are indicated to determine the risks and benefits, 
as well as the cost relative to the benefits for a number of 
conditions.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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